1 / 9

Continued Leadership in the DOV Collaboration

Continued Leadership in the DOV Collaboration. By Nike Grange. DOV.

morna
Download Presentation

Continued Leadership in the DOV Collaboration

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Continued Leadership in the DOV Collaboration By Nike Grange

  2. DOV Designed to develop a long-term plan by all Vaccine and Immunization stakeholders in order to scale up immunization programmes whilst maintaining a balance between activities that should lead to elimination of vaccine preventable diseases and those that will sustain routine immunization

  3. Costs not included • Cost for research & development of new vaccines • Cost of scaling up seasonal influenza vaccination • Increased Surveillance • Increased CSO engagement • Current & additional technical agency support

  4. Reasons for DOV • Cost-effectiveness of Immunization • Reduction in deaths • Reduction in Measles deaths by 74% • Reduction in Polio by 99% • Still sizable Gap in no of children unimmunised and under-immunised • Global disparities • Continuous emergence of new birth cohorts

  5. Goals • World free from Polio • Meet global and regional disease elimination targets • Understand value of vaccines and demand imunzation as a right • Immunization programmes to have sustainable access to predictable funding, quality supply and innovative technologies

  6. Benefits and Costs • 24-66 b No of deaths that cn be averted by reaching target immunization in 8 countries • $50-60 B Cost of scaling up routine immunization efforts & continue to provide accelerated disease control programs in 94 low and middle-income countries • $32 B Anticipated funding from Governments & GAVI Alliance. Funding from GAVI is dependent on donor $ country decisions • S18-28B Additional funding required

  7. Costs estimates based on: • Vaccines and Supplies • Transportation & Cold Chain • HUMAN RESOURCES • Training • No clinical supervision-to improve quality of care • Record keeping, data generation, storage, retrieval & dissemination Social Mobilization/Communication Surveillance & Programme Management

  8. R&D Goals • Operational & implementational research agenda • Basic research • New Vaccines • Platform vaccines & a research-based global regulatory agenda • New manufacturing technologies

  9. Leadership Council • WHO • Bill and Melinda Gates • US National Institute of allergy & Infectious Diseases • Sabin Vaccine institute-Polio& Measles

More Related